Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

David Sanford, Courtney D. Dinardo, Guilin Tang, Jorge E. Cortes, Srdan Verstovsek, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalArticle

Abstract

Background Jumping translocations (JT) are uncommon cytogenetic abnormalities involving nonreciprocal translocations of a single donor chromosome onto 2 or more chromosomes. The clinical characteristics and prognosis of JTs in patients with myeloid malignancies are not well described. Materials and Methods We searched our cytogenetic database from 2003 to 2014 to identify cases of myeloid malignancies associated with a JT. These cases were cross-referenced with our clinical databases to determine patient characteristics, response to treatment and overall survival. Results We identified 10 patients with myeloid malignancies and a JT: 4 cases of acute myeloid leukemia with myelodysplastic syndrome-related changes, 4 cases of myelodysplastic syndrome, and 2 cases of postpolycythemia myelofibrosis. The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late occurrence, with a median time to JT development of 24.9 months (range, 0-248 months) from diagnosis. The overall response to treatment was poor, with no patients experiencing a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95% confidence interval, 2.5-15.5) after identification of a JT. Conclusion The acquisition of a JT in patients with myeloid malignancies appears to be a late event and is associated with myelodysplasia. In our series, this was associated with a poor prognosis with a poor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival.

Original languageEnglish (US)
Article number608
Pages (from-to)556-562
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number9
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Survival
Myelodysplastic Syndromes
Neoplasms
Acute Myeloid Leukemia
Tissue Donors
Databases
Therapeutics
Primary Myelofibrosis
Chromosomes, Human, Pair 2
Chromosomes, Human, Pair 1
Cytogenetics
Chromosome Aberrations
Chromosomes
Confidence Intervals
Drug Therapy

Keywords

  • Jumping translocations
  • Leukemia
  • Myelodysplastic syndromes
  • Myeloid neoplasms
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. / Sanford, David; Dinardo, Courtney D.; Tang, Guilin; Cortes, Jorge E.; Verstovsek, Srdan; Jabbour, Elias; Ravandi, Farhad; Kantarjian, Hagop; Garcia-Manero, Guillermo.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, No. 9, 608, 01.09.2015, p. 556-562.

Research output: Contribution to journalArticle

Sanford, D, Dinardo, CD, Tang, G, Cortes, JE, Verstovsek, S, Jabbour, E, Ravandi, F, Kantarjian, H & Garcia-Manero, G 2015, 'Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival', Clinical Lymphoma, Myeloma and Leukemia, vol. 15, no. 9, 608, pp. 556-562. https://doi.org/10.1016/j.clml.2015.05.005
Sanford, David ; Dinardo, Courtney D. ; Tang, Guilin ; Cortes, Jorge E. ; Verstovsek, Srdan ; Jabbour, Elias ; Ravandi, Farhad ; Kantarjian, Hagop ; Garcia-Manero, Guillermo. / Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. In: Clinical Lymphoma, Myeloma and Leukemia. 2015 ; Vol. 15, No. 9. pp. 556-562.
@article{ae588c32f03a4e7a8146ae787be0e462,
title = "Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival",
abstract = "Background Jumping translocations (JT) are uncommon cytogenetic abnormalities involving nonreciprocal translocations of a single donor chromosome onto 2 or more chromosomes. The clinical characteristics and prognosis of JTs in patients with myeloid malignancies are not well described. Materials and Methods We searched our cytogenetic database from 2003 to 2014 to identify cases of myeloid malignancies associated with a JT. These cases were cross-referenced with our clinical databases to determine patient characteristics, response to treatment and overall survival. Results We identified 10 patients with myeloid malignancies and a JT: 4 cases of acute myeloid leukemia with myelodysplastic syndrome-related changes, 4 cases of myelodysplastic syndrome, and 2 cases of postpolycythemia myelofibrosis. The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late occurrence, with a median time to JT development of 24.9 months (range, 0-248 months) from diagnosis. The overall response to treatment was poor, with no patients experiencing a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95{\%} confidence interval, 2.5-15.5) after identification of a JT. Conclusion The acquisition of a JT in patients with myeloid malignancies appears to be a late event and is associated with myelodysplasia. In our series, this was associated with a poor prognosis with a poor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival.",
keywords = "Jumping translocations, Leukemia, Myelodysplastic syndromes, Myeloid neoplasms, Prognosis",
author = "David Sanford and Dinardo, {Courtney D.} and Guilin Tang and Cortes, {Jorge E.} and Srdan Verstovsek and Elias Jabbour and Farhad Ravandi and Hagop Kantarjian and Guillermo Garcia-Manero",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.clml.2015.05.005",
language = "English (US)",
volume = "15",
pages = "556--562",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "9",

}

TY - JOUR

T1 - Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

AU - Sanford, David

AU - Dinardo, Courtney D.

AU - Tang, Guilin

AU - Cortes, Jorge E.

AU - Verstovsek, Srdan

AU - Jabbour, Elias

AU - Ravandi, Farhad

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background Jumping translocations (JT) are uncommon cytogenetic abnormalities involving nonreciprocal translocations of a single donor chromosome onto 2 or more chromosomes. The clinical characteristics and prognosis of JTs in patients with myeloid malignancies are not well described. Materials and Methods We searched our cytogenetic database from 2003 to 2014 to identify cases of myeloid malignancies associated with a JT. These cases were cross-referenced with our clinical databases to determine patient characteristics, response to treatment and overall survival. Results We identified 10 patients with myeloid malignancies and a JT: 4 cases of acute myeloid leukemia with myelodysplastic syndrome-related changes, 4 cases of myelodysplastic syndrome, and 2 cases of postpolycythemia myelofibrosis. The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late occurrence, with a median time to JT development of 24.9 months (range, 0-248 months) from diagnosis. The overall response to treatment was poor, with no patients experiencing a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95% confidence interval, 2.5-15.5) after identification of a JT. Conclusion The acquisition of a JT in patients with myeloid malignancies appears to be a late event and is associated with myelodysplasia. In our series, this was associated with a poor prognosis with a poor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival.

AB - Background Jumping translocations (JT) are uncommon cytogenetic abnormalities involving nonreciprocal translocations of a single donor chromosome onto 2 or more chromosomes. The clinical characteristics and prognosis of JTs in patients with myeloid malignancies are not well described. Materials and Methods We searched our cytogenetic database from 2003 to 2014 to identify cases of myeloid malignancies associated with a JT. These cases were cross-referenced with our clinical databases to determine patient characteristics, response to treatment and overall survival. Results We identified 10 patients with myeloid malignancies and a JT: 4 cases of acute myeloid leukemia with myelodysplastic syndrome-related changes, 4 cases of myelodysplastic syndrome, and 2 cases of postpolycythemia myelofibrosis. The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late occurrence, with a median time to JT development of 24.9 months (range, 0-248 months) from diagnosis. The overall response to treatment was poor, with no patients experiencing a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95% confidence interval, 2.5-15.5) after identification of a JT. Conclusion The acquisition of a JT in patients with myeloid malignancies appears to be a late event and is associated with myelodysplasia. In our series, this was associated with a poor prognosis with a poor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival.

KW - Jumping translocations

KW - Leukemia

KW - Myelodysplastic syndromes

KW - Myeloid neoplasms

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84939563969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939563969&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2015.05.005

DO - 10.1016/j.clml.2015.05.005

M3 - Article

C2 - 26141213

AN - SCOPUS:84939563969

VL - 15

SP - 556

EP - 562

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 9

M1 - 608

ER -